Home・Listă Acțiuni・Innoviva Inc

Innoviva Inc

Închisă

SectorSănătate

21.18 2.52

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

20.51

Maxim

21.2

Indicatori cheie
By Trading Economics
Venit	-270M -83M
Vânzări	22M 120M
P/E Medie Sector	4.754 57.002
EPS	0.59
Marjă de profit	-69.754
Angajați	159
EBITDA	28M 267M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+96% upside

Dividende
By Acuity
Următoarele câștiguri	3 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-39M 1.5B
Deschiderea anterioară	18.66
Închiderea anterioară	21.18

Sentimentul știrilor

By Acuity

67%

33%

302 / 340 Clasament în Healthcare

Innoviva Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 aug. 2026, 19:56 UTC

Innoviva Inc shares are higher during Friday's session, recovering from earlier losses despite no specific news. Broader market sentiment is affected by declining U.S. retail sales.

13 aug. 2026, 19:41 UTC

Innoviva Inc shares are lower during Thursday's session, with no specific news identified. The stock remains below its 20-day moving average.

12 aug. 2026, 19:06 UTC

Event

Innoviva Inc's therapies are finalists for the 2026 Prix Galien USA Award, but shares are trading lower, remaining below Tuesday's close.

11 aug. 2026, 19:16 UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10 aug. 2026, 19:16 UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7 aug. 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 aug. 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 aug. 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 aug. 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 iul. 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 iul. 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 iul. 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 iul. 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 iul. 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 iul. 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 iul. 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Comparație

Modificare preț

Innoviva Inc Așteptări

Obiectiv de preț

By TipRanks

96% sus

Prognoză pe 12 luni

Medie 40.67 USD 96%

Maxim 46 USD

Minim 34 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruInnoviva Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor Innoviva Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

302 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.